Literature DB >> 15133698

Expression of the proto-oncogene c-KIT in normal and tumor tissues from colorectal carcinoma patients.

Innocenzo Sammarco1, Gabriele Capurso, Luigi Coppola, Antonio Paniccià Bonifazi, Sara Cassetta, Gianfranco Delle Fave, Alessandro Carrara, Giovanni Battista Grassi, Pellegrino Rossi, Claudio Sette, Raffaele Geremia.   

Abstract

BACKGROUND AND AIMS: The proto-oncogene c-KIT encodes a tyrosine kinase receptor essential during embryonic development and postnatal life. Although deregulated expression of c-KIT has been reported, its role in colorectal carcinoma remains controversial: some authors have described a correlation between c-KIT expression and colorectal cancer (CRC), while others have failed to detect the receptor in the majority of neoplasia examined. To address this question, we designed a prospective study to analyze the expression of c-KIT in normal and neoplastic colonic mucosa of the same patient. PATIENTS AND METHODS: We analyzed the tissues of 20 patients undergoing surgical resection for colorectal carcinoma by reverse transcriptase-polymerase chain reaction, Western blot and immunohistochemistry, whose results were correlated with histopathological parameters.
RESULTS: Most patients (90%) showed c-KIT expression in normal tissue both at RNA and protein level, while in neoplastic tissue it was observed in 30% of patients at RNA level and in 10% at protein level. By immunohistochemistry the localization of c-KIT protein in the normal colon was restricted to interstitial cells scattered in the stroma, whereas the non-neoplastic epithelium was always negative. The mucinous carcinomas were all c-KIT negative, whereas the only case in which c-KIT was displayed in the neoplastic epithelium was a G3 adenocarcinoma.
CONCLUSION: Most colorectal carcinomas do not express c-KIT. We suggest that c-KIT expression is rarely present in this neoplasia; thus, the use of receptor inhibitors should be conducted in selected sub-groups of colon carcinoma patients, subsequent to the clear demonstration of c-KIT overexpression in the neoplastic cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15133698     DOI: 10.1007/s00384-004-0601-9

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  34 in total

1.  A novel c-kit transcript, potentially encoding a truncated receptor, originates within a kit gene intron in mouse spermatids.

Authors:  P Rossi; G Marziali; C Albanesi; A Charlesworth; R Geremia; V Sorrentino
Journal:  Dev Biol       Date:  1992-07       Impact factor: 3.582

Review 2.  Recent advances in colorectal cancer therapy.

Authors:  Tracy S d'Entremont; Weijing Sun
Journal:  Cancer Biol Ther       Date:  2003 Jan-Feb       Impact factor: 4.742

3.  Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.

Authors:  Ramzi Dagher; Martin Cohen; Gene Williams; Mark Rothmann; Jogarao Gobburu; Gabriel Robbie; Atiqur Rahman; Gang Chen; Ann Staten; Donna Griebel; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2002-10       Impact factor: 12.531

4.  c-kit is expressed in soft tissue sarcoma of neuroectodermic origin and its ligand prevents apoptosis of neoplastic cells.

Authors:  E Ricotti; F Fagioli; E Garelli; C Linari; N Crescenzio; A L Horenstein; P Pistamiglio; S Vai; M Berger; L C di Montezemolo; E Madon; G Basso
Journal:  Blood       Date:  1998-04-01       Impact factor: 22.113

Review 5.  Tyrosine kinases as targets in cancer therapy - successes and failures.

Authors:  Peter Traxler
Journal:  Expert Opin Ther Targets       Date:  2003-04       Impact factor: 6.902

Review 6.  Validating immunohistochemical staining for KIT (CD117).

Authors:  Jason L Hornick; Christopher D M Fletcher
Journal:  Am J Clin Pathol       Date:  2003-03       Impact factor: 2.493

7.  Activating SRC mutation in a subset of advanced human colon cancers.

Authors:  R B Irby; W Mao; D Coppola; J Kang; J M Loubeau; W Trudeau; R Karl; D J Fujita; R Jove; T J Yeatman
Journal:  Nat Genet       Date:  1999-02       Impact factor: 38.330

8.  A comparative analysis of cancer prevalence in cancer registry areas of France, Italy and Spain.

Authors:  A Verdecchia; A Micheli; M Colonna; V Moreno; M I Izarzugaza; E Paci
Journal:  Ann Oncol       Date:  2002-07       Impact factor: 32.976

9.  Expression of c-kit receptor in normal and transformed human nonlymphoid tissues.

Authors:  P G Natali; M R Nicotra; I Sures; E Santoro; A Bigotti; A Ullrich
Journal:  Cancer Res       Date:  1992-11-15       Impact factor: 12.701

10.  Complementary DNA cloning and characterization of truncated form of c-kit in human colon carcinoma cells.

Authors:  M Toyota; Y Hinoda; F Itoh; A Takaoka; K Imai; A Yachi
Journal:  Cancer Res       Date:  1994-01-01       Impact factor: 12.701

View more
  19 in total

Review 1.  Synchronous colorectal adenocarcinoma and gastrointestinal stromal tumor (GIST).

Authors:  Marcovalerio Melis; Eugene A Choi; Robert Anders; Peter Christiansen; Alessandro Fichera
Journal:  Int J Colorectal Dis       Date:  2006-04-26       Impact factor: 2.571

2.  c-kit (CD117) expression in human tumors and its prognostic value: an immunohistochemical analysis.

Authors:  Michael Medinger; Manuela Kleinschmidt; Klaus Mross; Barbara Wehmeyer; Clemens Unger; Hans-Eckart Schaefer; Renate Weber; Marc Azemar
Journal:  Pathol Oncol Res       Date:  2010-02-23       Impact factor: 3.201

Review 3.  Tissue-based biomarkers predicting outcomes in metastatic colorectal cancer: a review.

Authors:  L Ung; A K-Y Lam; D L Morris; T C Chua
Journal:  Clin Transl Oncol       Date:  2014-01-24       Impact factor: 3.405

4.  Prognostic value of KIT mutation in gastrointestinal stromal tumors.

Authors:  Xiao-Hong Liu; Chen-Guang Bai; Qiang Xie; Fei Feng; Zhi-Yun Xu; Da-Lie Ma
Journal:  World J Gastroenterol       Date:  2005-07-07       Impact factor: 5.742

5.  Targeted molecular profiling of rare genetic alterations in colorectal cancer using next-generation sequencing.

Authors:  Mayank Jauhri; Akanksha Bhatnagar; Satish Gupta; Yogender Shokeen; Sachin Minhas; Shyam Aggarwal
Journal:  Med Oncol       Date:  2016-08-27       Impact factor: 3.064

6.  Poorly differentiated carcinoma of the rectum with aberrant immunophenotype: a case report.

Authors:  A Giannopoulos; I Papaconstantinou; P Alexandrou; A Petrou; A Papalambros; E Felekouras; E Papalambros
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

7.  Tandutinib inhibits the Akt/mTOR signaling pathway to inhibit colon cancer growth.

Authors:  Sivapriya Ponnurangam; David Standing; Parthasarathy Rangarajan; Dharmalingam Subramaniam
Journal:  Mol Cancer Ther       Date:  2013-02-20       Impact factor: 6.261

8.  Immunohistochemical detection of receptor tyrosine kinases c-kit, EGF-R, and PDGF-R in colorectal adenocarcinomas.

Authors:  Jan Friederichs; Claus W H von Weyhern; Robert Rosenberg; Dietrich Doll; Raymonde Busch; Florian Lordick; Jörg Rüdiger Siewert; Mario Sarbia
Journal:  Langenbecks Arch Surg       Date:  2009-03-12       Impact factor: 3.445

9.  A subset of colorectal carcinomas express c-KIT protein independently of BRAF and/or KRAS activation.

Authors:  Ana Preto; Cátia Moutinho; Sérgia Velho; Carla Oliveira; Ana Paula Rebocho; Joana Figueiredo; Paula Soares; José Manuel Lopes; Raquel Seruca
Journal:  Virchows Arch       Date:  2007-05-09       Impact factor: 4.064

10.  Expression of CK19 and KIT in resectable pancreatic neuroendocrine tumors.

Authors:  Xu Han; Jing Zhao; Yuan Ji; Xuefeng Xu; Wenhui Lou
Journal:  Tumour Biol       Date:  2013-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.